Many studies have already analyzed HER-2 and COX-2 expression in ductal carcinoma in situ and invasive ductal carcinoma, but most of these studies were carried out on samples from different women, thereby restricting the usefulness of these data for studying tumor progression. The gene discussed is ERBB2; the disease is neoplasm.